Bartel F - Search Results

1

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. Bond GL, et al. Among authors: bartel f. Cancer Res. 2006 May 15;66(10):5104-10. doi: 10.1158/0008-5472.CAN-06-0180. Cancer Res. 2006. PMID: 16707433 Free article.

2

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. Bond GL, et al. Among authors: bartel f. Cell. 2004 Nov 24;119(5):591-602. doi: 10.1016/j.cell.2004.11.022. Cell. 2004. PMID: 15550242 Free article.

3

MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.

Bartel F, Harris LC, Würl P, Taubert H. Bartel F, et al. Mol Cancer Res. 2004 Jan;2(1):29-35. Mol Cancer Res. 2004. PMID: 14757843 Review.

4

Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, Scaini MC, Bartel F, Böhnke A, Pempe C, Gradhand E, Hauptmann S, Offit K, Levine AJ, Bond GL. Atwal GS, et al. Among authors: bartel f. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10236-41. doi: 10.1073/pnas.0901298106. Epub 2009 Jun 4. Proc Natl Acad Sci U S A. 2009. PMID: 19497887 Free PMC article.

5

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG. Lenos K, et al. Among authors: bartel f. Cancer Res. 2012 Aug 15;72(16):4074-84. doi: 10.1158/0008-5472.CAN-12-0215. Epub 2012 Jun 14. Cancer Res. 2012. PMID: 22700878

6

Alternative and aberrant splicing of MDM2 mRNA in human cancer.

Bartel F, Taubert H, Harris LC. Bartel F, et al. Cancer Cell. 2002 Jul;2(1):9-15. doi: 10.1016/s1535-6108(02)00091-0. Cancer Cell. 2002. PMID: 12150820 Free article. Review.

7

Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines.

Bartel F, Taylor AC, Taubert H, Harris LC. Bartel F, et al. Oncol Res. 2001;12(11-12):451-7. doi: 10.3727/096504001108747459. Oncol Res. 2001. PMID: 11939408

8

Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas.

Taubert H, Bartel F, Greither T, Bache M, Kappler M, Köhler T, Böhnke A, Lautenschläger C, Schmidt H, Holzhausen HJ, Hauptmann S, Würl P. Taubert H, et al. Among authors: bartel f. Mol Cancer Res. 2008 Oct;6(10):1575-81. doi: 10.1158/1541-7786.MCR-07-2150. Mol Cancer Res. 2008. PMID: 18922973

9

Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients.

Taubert HW, Bartel F, Kappler M, Schuster K, Meye A, Lautenschläger C, Thamm-Mücke B, Bache M, Schmidt H, Holzhausen HJ, Würl P. Taubert HW, et al. Among authors: bartel f. Cancer. 2003 May 1;97(9):2273-8. doi: 10.1002/cncr.11326. Cancer. 2003. PMID: 12712483 Free article.

10

Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene.

Meye A, Würl P, Bache M, Bartel F, Grünbaum U, Mansa-ard J, Schmidt H, Taubert H. Meye A, et al. Among authors: bartel f. Cancer Lett. 2000 Feb 28;149(1-2):181-8. doi: 10.1016/s0304-3835(99)00356-0. Cancer Lett. 2000. PMID: 10737722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters